Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 4, 2017, Pages E590-E599

  Iyer, Shilpa S ^a,b   Bibollet Ruche, Frederic ^a   Sherrill Mix, Scott ^b   Learn, Gerald H ^a   Plenderleith, Lindsey ^c   Smith, Andrew G ^a   Barbian, Hannah J ^a,b   Russell, Ronnie M ^a,b   Gondim, Marcos V P ^a   Bahari, Catherine Y ^a   Shaw, Christiana M ^a   Li, Yingying ^a   Decker, Timothy ^a   Haynes, Barton F ^d   Shaw, George M ^a,b   Sharp, Paul M ^c   Borrow, Persephone ^e   Hahn, Beatrice H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1 transmission fitness; HIV 1 transmission pairs; Innate immunity; Mucosal HIV 1 transmission; Type I interferons

Indexed keywords

ALPHA2 INTERFERON; BETA INTERFERON; CD4 ANTIGEN; INTERFERON;

CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; FITNESS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS REPLICATION; VIRUS TRANSMISSION; FEMALE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PHYSIOLOGY; SPERM; TRANSMISSION; VAGINAL LAVAGE; VIRION; VIROLOGY;

FEMALE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON TYPE I; MALE; SEMEN; VAGINAL DOUCHING; VIRION; VIRUS REPLICATION;

EID: 85010934760     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1620144114     Document Type: Article

References (90)

1. UNAIDS (2016) Global AIDS Update 2016. Available at www.unaids.org/sites/default/files/media-asset/global-AIDS-update-2016-en.pdf. Accessed December 21, 2016.
2. Shaw GM, Hunter E (2012) HIV transmission. Cold Spring Harb Perspect Med 2(11): a006965.
3. Passmore JA, Jaspan HB, Masson L (2016) Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS 11(2):156-162.
4. Burgener A, McGowan I, Klatt NR (2015) HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol 36:22-30.
5. Haynes BF, et al. (2016) HIV-host interactions: Implications for vaccine design. Cell Host Microbe 19(3):292-303.
6. Hladik F, McElrath MJ (2008) Setting the stage: Host invasion by HIV. Nat Rev Immunol 8(6):447-457.
7. Keele BF, Estes JD (2011) Barriers to mucosal transmission of immunodeficiency viruses. Blood 118(4):839-846.
8. Joseph SB, Swanstrom R, Kashuba AD, Cohen MS (2015) Bottlenecks in HIV-1 transmission: Insights from the study of founder viruses. Nat Rev Microbiol 13(7):414-425.
9. Keele BF, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21): 7552-7557.
10. Boeras DI, et al. (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci USA 108(46):E1156-E1163.
11. Carlson JM, et al. (2014) HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 345(6193):1254031.
12. Bar KJ, et al. (2010) Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 84(12):6241-6247.
13. Li H, et al. (2010) High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 6(5):e1000890.
14. Salazar-Gonzalez JF, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206(6):1273-1289.
15. Salazar-Gonzalez JF, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82(8):3952-3970.
16. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJ (1990) Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol 64(12):5840-5850.
17. Palmer S, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43(1):406-413.
18. Liu SL, et al. (1996) HIV quasispecies and resampling. Science 273(5274):415-416.
19. Abrahams MR, et al.; CAPRISA Acute Infection Study Team; Center for HIV-AIDS Vaccine Immunology Consortium (2009) Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 83(8):3556-3567.
20. Haaland RE, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5(1): e1000274.
21. Tully DC, et al. (2016) Differences in the selection bottleneck between modes of sexual transmission influence the genetic composition of the HIV-1 founder virus. PLoS Pathog 12(5):e1005619.
22. Wilen CB, et al. (2011) Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85(17):8514-8527.
23. Parrish NF, et al. (2012) Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog 8(5):e1002686.
24. Ping LH, et al.; CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium (2013) Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 87(13):7218-7233.
25. Ochsenbauer C, et al. (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86(5):2715-2728.
26. Parrish NF, et al. (2013) Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 110(17):6626-6633.
27. Deymier MJ, et al. (2015) Heterosexual transmission of subtype C HIV-1 selects consensus-like variants without increased replicative capacity or interferon-α resistance. PLoS Pathog 11(9):e1005154.
28. Oberle CS, et al.; Swiss HIV Cohort Study (2016) Tracing HIV-1 transmission: Envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology 13(1):62.
29. Altfeld M, Gale M, Jr (2015) Innate immunity against HIV-1 infection. Nat Immunol 16(6):554-562.
30. Stetson DB, Medzhitov R (2006) Type I interferons in host defense. Immunity 25(3): 373-381.
31. Schoggins JW (2014) Interferon-stimulated genes: Roles in viral pathogenesis. Curr Opin Virol 6:40-46.
32. Doyle T, Goujon C, Malim MH (2015) HIV-1 and interferons: Who's interfering with whom? Nat Rev Microbiol 13(7):403-413.
33. Towers GJ, Noursadeghi M (2014) Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe 16(1):10-18.
34. Sandler NG, et al. (2014) Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511(7511):601-605.
35. Veazey RS, et al. (2016) Prevention of SHIV transmission by topical IFN-β treatment. Mucosal Immunol 9(6):1528-1536.
36. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ (2005) Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 79(19):12164-12172.
37. Stacey AR, et al. (2009) Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83(8): 3719-3733.
38. Frater AJ, et al. (2007) Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 81(12):6742-6751.
39. Crawford H, et al. (2009) Evolution of HLA-B∗5703 HIV-1 escape mutations in HLAB∗ 5703-positive individuals and their transmission recipients. J Exp Med 206(4): 909-921.
40. Ganusov VV, et al. (2011) Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol 85(20):10518-10528.
41. Bar KJ, et al. (2012) Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 8(5):e1002721.
42. Song H, et al. (2012) Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 9:89.
43. Sather DN, et al. (2012) Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J Virol 86(23):12676-12685.
44. Yue L, et al. (2015) Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog 11(1): e1004565.
45. Lynch RM, et al. (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89(8):4201-4213.
46. Politch JA, Marathe J, Anderson DJ (2014) Characteristics and quantities of HIV host cells in human genital tract secretions. J Infect Dis 210(Suppl 3):S609-S615.
47. Cummings MP, Neel MC, Shaw KL (2008) A genealogical approach to quantifying lineage divergence. Evolution 62(9):2411-2422.
48. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72(4):2855-2864.
49. Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46(6):1896-1905.
50. Eron JJ, et al. (2004) Short-term safety and antiretroviral activity of T-1249, a secondgeneration fusion inhibitor of HIV. J Infect Dis 189(6):1075-1083.
51. Ribeiro RM, et al. (2010) Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 84(12):6096-6102.
52. Fenton-May AE, et al. (2013) Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10:146.
53. Song H, et al. (2016) Transmission of multiple HIV-1 subtype C transmitted/founder viruses into the same recipients was not determined by modest phenotypic differences. Sci Rep 6:38130.
54. Kmiec D, et al. (2016) Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. MBio 7(4):e00934-16.
55. Gnanakaran S, et al. (2011) Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 7(9): e1002209.
56. Parker ZF, et al. (2013) Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 87(5):2401-2411.
57. Foster TL, et al. (2016) Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 20(4):429-442.
58. Etemad B, et al. (2014) Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology 11:106.
59. Isaacman-Beck J, et al. (2009) Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 83(16):8208-8220.
60. Künzi MS, Farzadegan H, Margolick JB, Vlahov D, Pitha PM (1995) Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression. J Infect Dis 171(4):822-828.
61. Edlin BR, et al. (1992) In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: Correlations with treatment duration and response. Ann Intern Med 117(6):457-460.
62. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2(3):193-203.
63. Van Damme N, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3(4):245-252.
64. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177):425-430.
65. Jafari M, Guatelli J, Lewinski MK (2014) Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. J Virol 88(9):5062-5078.
66. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898): 646-650.
67. Stremlau M, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427(6977):848-853.
68. Ribeiro C, et al. (2016) Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets. Nature 540(7633):448-452.
69. Laguette N, et al. (2011) SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474(7353):654-657.
70. Hrecka K, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474(7353):658-661.
71. Goujon C, et al. (2013) Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502(7472):559-562.
72. Liu Z, et al. (2013) The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14(4):398-410.
73. Li M, et al. (2012) Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 491(7422):125-128.
74. Lavoie TB, et al. (2011) Binding and activity of all human alpha interferon subtypes. Cytokine 56(2):282-289.
75. Gibbert K, Schlaak JF, Yang D, Dittmer U (2013) IFN-α subtypes: Distinct biological activities in anti-viral therapy. Br J Pharmacol 168(5):1048-1058.
76. Jaks E, Gavutis M, Uzé G, Martal J, Piehler J (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366(2): 525-539.
77. Schreiber G, Piehler J (2015) The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol 36(3):139-149.
78. de Weerd NA, et al. (2013) Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat Immunol 14(9):901-907.
79. Lavender KJ, et al. (2016) Interferon alpha subtype-specific suppression of HIV-1 infection in vivo. J Virol 90(13):6001-6013.
80. Harper MS, et al. (2015) Interferon-α subtypes in an ex vivo model of acute HIV-1 infection: Expression, potency and effector mechanisms. PLoS Pathog 11(11):e1005254.
81. Künzi MS, Pitha PM (1996) Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. J Interferon Cytokine Res 16(11):919-927.
82. Cope AB, et al. (2015) Ongoing HIV transmission and the HIV care continuum in North Carolina. PLoS One 10(6):e0127950.
83. Larkin MA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23(21): 2947-2948.
84. Guindon S, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 59(3):307-321.
85. Darriba D, Taboada GL, Doallo R, Posada D (2012) jModelTest 2: More models, new heuristics and parallel computing. Nat Methods 9(8):772.
86. Stamatakis A (2014) RAxML version 8: A tool for phylogenetic analysis and postanalysis of large phylogenies. Bioinformatics 30(9):1312-1313.
87. Gelman A, Carlin J, Stern H, Rubin D (2003) Bayesian Data Analysis (Chapman & Hall/CRC, New York, NY), 2nd Ed.
88. Carpenter B, et al., Stan: A probabilistic programming language. J Stat Softw, in press.
89. R Development Core Team (2016) A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna). Available at https://www. R-project.org/. Accessed December 21, 2016.
90. Robin X, et al. (2011) pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77.